The use of ertapenem for the treatment of lower extremity infections.

Abstract

Lower extremity infections are a growing challenge. Moderate to severe infections are frequently polymicrobial in nature and require appropriate parenteral antibiotic therapy. Ideally, empiric treatment should be broad spectrum in coverage, simplistic in use, and economically reasonable for the patient and the health care system. This article retrospectively reviewed the outcomes of 230 patients, 159 (69.13%) of whom were diabetic, who were admitted with lower extremity infections and who were empirically treated with ertapenem. Ertapenem was well tolerated with a low adverse effect profile. We found a 79.13% rate (182 of 230 patients) of favorable outcome with this regimen, which is comparable to other published studies that have looked at the use of this agent. Ertapenem is a once-daily, broad-spectrum carbapenem antibiotic indicated for the treatment of complicated skin and skin-structure infections (cSSSI). Ertapenem is an appropriate choice for empiric antibiotic therapy of lower extremity infections. 2.